Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ANRO vs ICCC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ICCC Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–1 Matrix Metrics)

ICCC Overall Winner 6-Pillar Tally: ANRO 1 – 5 ICCC Matrix Metrics: ANRO 1 – 8 ICCC

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Alto Neuroscience Inc. (ANRO) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ANRO carries a Unified Composite Score of 29.2/100 (SELL) at $27.12 (N/M Forward P/E, 0.0% operating margin), whereas ICCC carries 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin).

  • Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 54.3); meanwhile ICCC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANRO vs ICCC
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$27.12
-8.19% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.95β · 90% Vol
Unified Composite Score
29.2 / 100 SELL
Tech 50.0 Fund 33.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.3 · SMA20: $24.83 · SMA50: $26.20
ICCC NASDAQ Head-to-Head Winner
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
TTM Revenue $67M
Forward P/E N/M
Beta / 30D Vol 0.24β · 46% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.9% over 20 days), RSI 68
RSI-14: 67.5 · SMA20: $10.37 · SMA50: $10.13

6-Pillar Scorecard Institutional Category Breakdown (ANRO 1 – 5 ICCC)

Columns: Metric · ANRO · ICCC
1. Valuation Multiples ICCC
Forward P/E N/M N/M
Trailing P/E N/M 56.6x
PEG Ratio N/M N/M
EV / Revenue N/M 1.6x
2. Growth & Scale ICCC
Revenue Growth (YoY) +0.0% +11.5%
Earnings Growth (YoY) +0.0% +259.9%
TTM Revenue (USD) N/A $67M
Market Cap $1.2B $97.7M
3. Profitability & Quality ICCC
Gross Margin N/A 40.3%
Operating Margin 0.0% 15.2%
Net Profit Margin 0.0% 2.6%
Return on Equity (ROE) -46.7% 2.6%
4. Balance Sheet & Cash Flow ICCC
Cash Generation (TTM) -$80M $7.4M
Cash Flow Margin N/A 11.0%
Net Cash / Leverage $301M Net Cash $13M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANRO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 79.4% (8th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat ICCC
OpEx & R&D Intensity N/A 25.1% of Rev ($17M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANRO (1) vs ICCC (8)
Institutional Metric ANRO ICCC Criterion Row Edge
Market Capitalization
Scale
$1.2B $97.7M Larger Scale ANRO
Trailing P/E Ratio
Valuation
N/M 56.6x Lower Multiple ICCC
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +11.5% Higher Growth ICCC
Operating Margin (TTM)
Profitability
0.0% 15.2% Higher Margin ICCC
Net Profit Margin
Profitability
0.0% 2.6% Higher Margin ICCC
Return on Equity (ROE)
Capital Efficiency
-46.7% 2.6% Higher ROE ICCC
52-Week Range Position
Momentum
61% ($11–$37) 91% ($5–$12) Stronger Trend ICCC
Beta / 30D Volatility
Risk Regime
1.95β · 90% Vol 0.24β · 46% Vol Lower Realized Risk ICCC
Unified Institutional Score
Composite Signal
29.2 / 100 (SELL) 43.8 / 100 (HOLD) Higher Composite ICCC
Trailing 12M Revenue (USD)
Operating Scale
N/A $67M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 40.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$80M ($301M Net Cash) $7.4M ($13M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANRO +17.38 pp
ANRO: +23.61% · ICCC: +6.23%
3M Horizon ICCC +37.55 pp
ANRO: -20.54% · ICCC: +17.01%
6M Horizon ANRO +9.16 pp
ANRO: +24.4% · ICCC: +15.24%
1Y Horizon ANRO +50.18 pp
ANRO: +138.94% · ICCC: +88.76%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs ICCC. Trailing 12-month operating profitability (ANRO 0.0% vs ICCC 15.2%) and valuation multiples (ANRO N/M vs ICCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M
ICCC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$67M
Gross Margin40.3%
Op. Margin15.2%
ROE / Fwd P/E2.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANRO BREAKDOWN
57d in phase · OBV ACCUMULATION
Current IV 79.4%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ICCC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ICCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ICCC Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.7M market capitalization and 15.2% operating margin.
OpEx & R&D Reinvestment 25.1% of Rev ($17M)
90D Engineering Disclosures 0 Published

Investor FAQ ANRO vs ICCC Key Questions & Quantitative Answers

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Alto Neuroscience Inc. (ANRO) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ANRO carries a Unified Composite Score of 29.2/100 (SELL) at $27.12 (N/M Forward P/E, 0.0% operating margin), whereas ICCC carries 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin). Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 54.3); meanwhile ICCC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ICCC leads the Growth & Scale pillar: ANRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ICCC at +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin). On trailing 12-month operating scale, ANRO generates N/A in USD-normalized revenue versus $67M for ICCC. In operating R&D and SG&A reinvestment, ANRO deploys N/A (0 90-day corporate R&D disclosures) versus 25.1% of Rev ($17M) (0 disclosures) for ICCC.

ICCC screens cheaper on headline valuation multiples. ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANRO (-46.7% ROE) versus ICCC (2.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.95β · 90% Vol realized risk). By comparison, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.